Totaled health risks in vascular events score predicts clinical outcome and symptomatic intracranial hemorrhage in chinese patients after thrombolysis

Stroke. 2015 Mar;46(3):864-6. doi: 10.1161/STROKEAHA.114.007979. Epub 2015 Feb 3.

Abstract

Background and purpose: The performance of the Totaled Health Risks in Vascular Events (THRIVE) score in predicting clinical outcomes in Chinese patients with acute ischemic stroke post intravenous thrombolysis is unknown.

Methods: Data from the Thrombolysis Implementation and Monitor of Acute Ischemic Stroke in China (TIMS-China) study was used to compare the THRIVE score with other scores used to predict clinical outcomes and symptomatic intracranial hemorrhage after intravenous thrombolysis.

Results: Among the 1128 patients with acute ischemic stroke who were included in this study, areas under the curve of the THRIVE score for symptomatic intracranial hemorrhage, 3-month poor functional outcomes, and death rate were 0.69, 0.71, and 0.78, respectively. The increased THRIVE score was related to the higher risk of developing symptomatic intracranial hemorrhage, poor functional outcomes, or death in patients with acute ischemic stroke at 3 months after thrombolysis.

Conclusions: The THRIVE score predicted reliably the risks of developing symptomatic intracranial hemorrhage, poor functional outcome, or death after intravenous thrombolysis therapy in Chinese patients with acute ischemic stroke.

Keywords: prognosis; stroke; thrombolytic therapy.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aged
  • Brain Ischemia / rehabilitation*
  • Calibration
  • China
  • Female
  • Fibrinolytic Agents / therapeutic use
  • Humans
  • Infusions, Intravenous
  • Intracranial Hemorrhages / rehabilitation*
  • Male
  • Middle Aged
  • Predictive Value of Tests
  • Prospective Studies
  • Registries
  • Reproducibility of Results
  • Risk Assessment
  • Severity of Illness Index
  • Stroke Rehabilitation
  • Thrombolytic Therapy / methods*
  • Treatment Outcome

Substances

  • Fibrinolytic Agents